| Source: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Type: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk: by definition reduces risk of disease or cancer. Down Target direction of risk indicates lower cancer risk. ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive.
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral
|
| 7327- | GSE, | Dietary-feeding of grape seed extract prevents azoxymethane-induced colonic aberrant crypt foci formation in fischer 344 rats |
| - | in-vivo, | CRC, | NA |
| 7473- | HRT, | Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials |
| - | Review, | BC, | NA |
| 7474- | HRT, | Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women |
| - | Review, | BC, | NA |
| 7475- | HRT, | Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial |
| - | Review, | Lung, | NA |
| 7478- | HRT, | Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations |
| - | Review, | BC, | NA |
| 7605- | I3C, | Indole-3-carbinol and prostate cancer |
| - | Review, | Pca, | NA |
| 7593- | I3C, | Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells |
| - | Review, | Pca, | NA |
| 7648- | Ins, | Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol |
| - | in-vivo, | Liver, | NA |
| 7676- | iod, | Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR) |
| - | in-vivo, | BC, | NA |
| 7685- | iod, | Could iodine be the missing micronutrient in breast cancer development? |
| - | Review, | BC, | NA |
| 2172- | iod, | A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey |
| - | Study, | Pca, | NA |
| - | in-vivo, | BC, | NA |
| 7659- | IP, | Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data |
| - | in-vivo, | Colon, | NA |
| 7712- | IP6, | Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice |
| - | in-vivo, | Pca, | NA |
| 7727- | IP6, | Suppression of colonic cancer by dietary phytic acid |
| - | Review, | Nor, | NA |
| 7740- | isoFl, | Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial |
| - | Trial, | Pca, | NA |
| 7739- | isoFl, | Soy, red clover, and isoflavones and breast cancer: a systematic review |
| - | Review, | BC, | NA |
| 7737- | isoFl, | An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health |
| - | Review, | Nor, | NA |
| 7735- | isoFl, | Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy |
| - | Review, | Var, | NA |
| 7841- | ISQ, | Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease |
| - | Human, | CardioV, | NA |
| 9183- | ITCs, | PEITC, | Isothiocyanates: translating the power of plants to people |
| - | Review, | Var, | NA |
| 9191- | ITCs, | AITC, | BITC, | PEITC, | SFN | Molecular Targets of Isothiocyanates in Cancer: Recent Advances |
| - | Review, | Var, | NA |
| 9193- | ITCs, | PEITC, | BITC, | SFN, | Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research |
| - | Review, | Var, | NA |
| 4010- | K+, | Potassium-sparing diuretics might reduce risk of Alzheimer's disease |
| - | Review, | AD, | NA |
| 4005- | K+, | Potassium |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA |
| 8095- | KAE, | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| - | Review, | Var, | NA |
| 8071- | KAE, | Cellular reprogramming and signaling control by kaempferol in colorectal cancer |
| - | Review, | CRC, | NA |
| 8061- | KAE, | Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 8062- | KAE, | A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer |
| - | Study, | Ovarian, | NA |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8116- | LA, | Associations of Cervicovaginal Lactobacilli With High-Risk Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia, and Cancer: A Systematic Review and Meta-Analysis |
| - | Review, | Cerv, | NA |
| 1789- | LEC, | Risk.33.aspx">Lecithin Supplements and Breast Cancer Risk |
| - | Analysis, | BC, | NA |
| 8124- | LF, | Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine |
| - | Trial, | CRC, | NA |
| 8298- | lign, | Inhibitory Effects of Enterolactone on Growth and Metastasis in Human Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8345- | Lut, | Lutein inhibits breast cancer cell growth by suppressing antioxidant and cell survival signals and induces apoptosis |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8354- | Lut, | Zeax, | The Associations of Plasma/Serum Carotenoids with Alzheimer's Disease: A Systematic Review and Meta-Analysis |
| - | Study, | AD, | NA |
| 8343- | Lut, | Association of Lutein with Cancer: A Systematic Review of the Lutein Effects on Cellular Processes Involved in Cancer Progression |
| - | Review, | Var, | NA |
| 4195- | Lut, | Zeax, | Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer’s Disease |
| - | Human, | AD, | NA |
| 3816- | Lyco, | Lut, | Zeax, | Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults |
| - | Review, | AD, | NA |
| 8420- | Lyco, | Anticancer activity of lycopene in HT-29 colon cancer cell line |
| - | in-vitro, | CRC, | HT-29 |
| - | Review, | Var, | NA |
| 8409- | Lyco, | Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy |
| - | Trial, | Pca, | NA |
| 7742- | Lyco, | isoFl, | Lycopene and soy isoflavones in the treatment of prostate cancer |
| - | Trial, | Pca, | NA |
| 4786- | Lyco, | Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | SkBr3 |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4799- | Lyco, | Anticancer Properties of Lycopene |
| - | Review, | Var, | NA |
| - | Review, | Var, | NA |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4796- | Lyco, | The Anti-proliferation Effects of Lycopene on Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 4793- | Lyco, | Lycopene treatment inhibits activation of Jak1/Stat3 and Wnt/β-catenin signaling and attenuates hyperproliferation in gastric epithelial cells |
| - | in-vitro, | GC, | AGS |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:785 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid